Treatment with tamoxifen

Soft tissue sarcoma - Treatment with tamoxifen Factor

Last reviewed for CCPS 20 August 2008.

Preliminary questions [30708]

16833 there is some evidence that treatment with tamoxifen may be a factor in the development of the condition under consideration.

30669 the condition under consideration is a uterine sarcoma.

14054

the veteran has been treated with tamoxifen at some time.

36193 — the veteran has established the causal connection between undergoing treatment with tamoxifen and VEA service for the clinical onset of soft tissue sarcoma.

36194 — the veteran has established the causal connection between undergoing treatment with tamoxifen and eligible service for the clinical onset of soft tissue sarcoma.

or

30711 — the veteran has established the causal connection between undergoing treatment with tamoxifen and operational service for the clinical onset of soft tissue sarcoma.

Clinical onset and operational service [30711]

36195 the veteran has undergone treatment with tamoxifen for a period of at least two months at some time.

36197

the veteran underwent treatment with tamoxifen for a period of at least two months before the clinical onset of the condition under consideration.

14056

the treatment with tamoxifen was given for an illness or injury which is identifiable.

36199

the veteran underwent treatment with tamoxifen for a period of at least two months before the clinical onset of the condition under consideration for treatment of an illness or injury which is identifiable.

14060 — the identified illness or injury for which the treatment with tamoxifen was given is causally related to operational service.

Clinical onset and eligible service [36194]

36196

the veteran has undergone treatment with tamoxifen for a period of at least four months at some time.

36198

the veteran underwent treatment with tamoxifen for a period of at least four months before the clinical onset of the condition under consideration.

14056

the treatment with tamoxifen was given for an illness or injury which is identifiable.

36200

the veteran underwent treatment with tamoxifen for a period of at least four months before the clinical onset of the condition under consideration for treatment of an illness or injury which is identifiable.

14061 — the identified illness or injury for which the treatment with tamoxifen was given is causally related to eligible service.